


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	TOFACITINIB CITRATE
PRONUNCIATION	toe" fa sye' ti nib si' trate
THERAPEUTIC CLAIM	Treatment of immunological disorders

CHEMICAL NAMES

- 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-ylamino)- β -oxo-, (3*R*,4*R*)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
- 3-((3*R*,4*R*)-4-methyl-3-[methyl(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]piperidin-1-yl)-3-oxo-propanenitrile, 2-hydroxypropane-1,2,3-tricarboxylate (1:1)

STRUCTURAL FORMULA



MOLECULAR FORMULA	$C_{16}H_{20}N_6O \cdot C_6H_8O_7$
MOLECULAR WEIGHT	504.5
TRADEMARK	None as yet
MANUFACTURER	Pfizer
CODE DESIGNATION	CP-690550-10
<u>CAS</u> REGISTRY NUMBER	540737-29-9

NOTE: This statement supersedes adopted name *tasocitinib citrate* (N10/37). The adoption of *tasocitinib citrate* is hereby rescinded.